Home / Market News / $BEAM
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Wedbush Adjusts Price Target on Beam Therapeutics

Nov 3, 2026, 11:11 PM UTC · Primary ticker $BEAM

Wedbush has increased its price target for Beam Therapeutics from $28 to $30, while reiterating an Outperform rating. This adjustment follows the company's Q3 2026 financial results and reflects the analyst's updated assessment of Beam's clinical and financial trajectory, suggesting a moderately positive outlook.

Wedbush adjusted its price target for Beam Therapeutics from $28 to $30, maintaining an Outperform rating, after the company's third-quarter 2026 financial results. This action indicates that the analyst firm views Beam's recent performance and future prospects, particularly its clinical and financial progress, more favorably than before. For traders, this represents a moderately positive signal, potentially leading to short-term upward price momentum as the market digests the analyst's updated outlook. The long-term implications depend on whether Beam can continue to meet or exceed expectations, validating the analyst's increased confidence. The key opportunity for traders is to capitalize on any immediate positive sentiment, while the risk lies in the possibility that the market has already priced in this adjustment or that future company performance may not align with the analyst's optimistic view.

$BEAM positive Analyst price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.